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Human immunodeﬁciency virus type-1 (HIV-1)-speciﬁc dendritic cell (DC) vaccines have been applied to
clinical trials that show only induction of some degree of immune responses, warranting the search of
other more efﬁcient vaccine strategies. Since HIV-1-speciﬁc CD8+ cytotoxic T lymphocytes (CTLs) have
been found to recognize some HIV-1 structural protein Gag conserved and cross-strain epitopes, Gag
has become one of the most attractive target candidates for HIV-1 vaccine development. In this study,
we generated HIV-1 Gag-speciﬁc Gag-Texo vaccine by using ConA-stimulated polyclonal CD8+ T-cells
with uptake of Gag-expressing adenoviral vector AdVGag-transfected DC (DCGag)-released exosomes
(EXOs), and assessed its stimulation of Gag-speciﬁc CD8+ CTL responses and antitumor immunity. We
demonstrate that Gag-Texo and DCGag vaccines comparably stimulate Gag-speciﬁc effector CD8
+ CTL
responses. Gag-Texo-stimulated CTL responses result in protective immunity against Gag-expressing
BL6-10Gag melanoma in 8/8 wild-type C57BL/6 mice. In addition, we show that Gag-Texo vaccine also
induces CTL responses leading to protective and long-term immunity against Gag/HLA-A2-expressing
BL6-10Gag/A2 melanoma in 8/8 and 2/8 transgenic HLA-A2 mice, respectively. The average number of lung
tumor colonies in mice with 30-days post-immunization is only 23, which is signiﬁcantly less than that
(>300) in control ConA-T-immunized HLA-A2 mice. Furthermore, Gag-Texo vaccine also induces some
degree of therapeutic immunity. The average number (50) and size (0.23 mm in diameter) of lung tumor
colonies in Gag-Texo-immunized HLA-A2 mice bearing 6-day-established lung BL6-10Gag/A2 melanoma
metastasis are signiﬁcantly less than the average number (>300) and size (1.02 mm in diameter) in con-
trol ConA-T-immunized HLA-A2 mice. Taken together, HIV-1 Gag-Texo vaccine capable of stimulating
Gag-speciﬁc CTL responses and therapeutic immunity may be useful as a new immunotherapeutic vac-
cine for viral control in HIV-1 patients.
 2013 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Immune surveillance by CD8+ cytotoxic T lymphocytes (CTLs)
represents a major mechanism for the detection and elimination
of cells infected with intracellular pathogens, especially viruses.
CTLs are also essential for effective immunity against human
immunodeﬁciency virus type 1 (HIV-1), and the induction of suchresponses using vaccines has become a major objective in the
strategy to halt the pandemic [1]. HIV-1 structural proteins such
as Gp120 and Gag are the major targets in vaccine development
[2,3]. Dendritic cells (DCs), the most potent antigen presenting
cells (APCs), play an important role in inducing CD4+ T-cell depen-
dent CTL responses [4]. DCs expressing HIV-1 Gp120 and Gag have
been used as vaccines to stimulate HIV-1-speciﬁc CTL responses in
animal models [5–8]. HIV-1-speciﬁc DC vaccines have been also
applied to clinical trials [9–12]. However, they have been found
to only induce some degree of immune responses in these clinical
trials [13], warranting the search of other more efﬁcient vaccine
strategies.
20 R. Wang et al. / Trials in Vaccinology 3 (2014) 19–25We previously developed a novel CD4+ T cell-based vaccine
(OVA-Texo) using CD4+ T-cells with uptake of ovalbumin (OVA)-
speciﬁc DC-released exosomes (EXO) [14–16]. We demonstrated
that CD4+ OVA-Texo vaccine is capable of stimulating potent
OVA-speciﬁc CTL responses and long term immunity via IL-2/
CD80 and CD40L signaling and counteracting regulatory T cell-
mediated immune suppression, and is also capable of inducing
more efﬁcient immunity than DC vaccine [14–16]. In addition,
we have recently demonstrated that ConA-stimulated mouse
CD8+ T cells with uptake of HIV-1 Gp120-speciﬁc DC-released
EXO (EXOGp120) can also be used as CD8+ Gp120-Texo vaccine capa-
ble of stimulating Gp120-speciﬁc CTL responses leading to thera-
peutic and long-term immunity against Gp120-expressing B16
melanoma in both wild-type C57BL/6 and transgenic HLA-A2 mice
[17,18].
CD8+ CTLs capable of recognizing some conserved and cross-
strain epitopes [19–21] play a critical role in control of HIV-1 pro-
liferation [22,23], acute phase of infection and disease progression
even in the absence of neutralizing Abs [3,24]. Monkeys immu-
nized with viral vectors developed cellular immune responses that
did slow disease progression [25,26]. Thus, CTLs become essential
for effective immunity against HIV-1 infection [1]. Compared to
HIV-1 structural protein Gp120, HIV-1 Gag has the following
advantages as a target antigen for developing HIV-1-speciﬁc vac-
cines. Gag as a viral antigen can enter the defective ribosomal
product (Drip) pathway [27], leading to enhanced major histocom-
patibility complex (MHC)-1 antigen presentation and CD8+ T-cell
activation [28]. Gag vaccine thus stimulated persistent and broader
CTL responses against conserved Gag epitopes in animal models
[21,29,30]. HLA-B57 HIV-1-infected individuals have also been
found to have autologous CTL responses against four conserved
Gag epitopes, leading to reducing virus replication and viral control
[31]. In addition, effective CTL responses against Gag, but not other
viral antigens, have been found to correlate with suppression of
HIV-1 replication in HIV-1 patients [32–35]. Therefore, Gag has be-
come one of the most attractive target candidates for HIV-1 vac-
cine development.
In this study, we generated Gag-Texo vaccine by using ConA-
stimulated mouse CD8+ T cells with uptake of Gag-speciﬁc DC-re-
leased EXOs, and assessed its stimulation of Gag-speciﬁc CTL re-
sponses and immunity against Gag-expressing B16 melanoma in
both wild-type C57BL/6 and transgenic HLA-A2 mice.Materials and methods
Reagents, cell lines and animals
Biotin-labeled or ﬂuorescein isothiocyanate (FITC)-labeled anti-
bodies (Abs) speciﬁc for H-2Kb, Iab, CD8, CD11c, CD40, CD54, CD80,
CD86, 4-1BBL, OX40L and HLA-A2 antibodies (Abs), FITC-conju-
gated avidin and PE-anti-IFN-r and PE-anti-CD44 Abs were all ob-
tained from BD Biosciences (Mississauga, Ontario, Canada). The
rabbit anti-Gag polyclonal Ab was obtained from Fisher Scientiﬁc
Inc, Waltham, MA. The Gag76–84 peptide (SLYNTVATL) and the
irrelevant control human epidermal growth factor receptor-2
(HER2) peptide (ILHNGAYSL) were synthesized by Multiple Peptide
Systems (San Diego, CA). Adenoviral vector AdVGag expressing HIV-
1 Gag was constructed by insertion of Gag cDNA fragment of
pcDNAGag into pShuttle vector (Stratagene, La Jolla, CA) by recom-
binant technology. The recombinant AdVGag vector was linealized
by PacI digestion, and then transfected into 293 cells using Lipo-
fectamine 2000 (Invitrogene, Carlsbad, CA) to generate AdVGag
expressing transgene Gag (Fig. 1A). AdVGag was ampliﬁed in 293
cells, and puriﬁed by a series of cesium chloride ultracentrifugation
gradients [36]. Vectors pcDNAHLA-A2 expressing a1 and a2 domainsof HLA-A2 and a3 domain of H-2Kb and vector pcDNA-Gag/GFP
expressing a fused gene Gag/GFP were previously constructed in
our laboratory [15]. B16 melanoma cell line BL6-10 was transfec-
ted with pcDNA-Gag/GFP by Lipofectamine 2000 (Invitrogene) to
generate BL6-10Gag/GFP cells, which were then further transfected
with pcDNAHLA-A2 to form Gag/HLA-A2-expressing BL6-10Gag/A2.
Female C57BL/6 and transgenic (Tg) HLA-A2 mice (#3584) were
obtained from the Jackson Laboratory (Bar Harbor, MA). All mice
were treated according to animal care committee guidelines of
the University of Saskatchewan.
Dendritic cell and exosome preparations
Bone marrow-derived dendritic cells (DCs) were obtained by
culturing the wild-type C57BL/6 or transgenic HLA-A2 mouse bone
marrow cells in culture medium containing GM-CSF (20 ng/ml)
and IL-4 (20 ng/ml) for 6 days as previously described [15]. DCs
were infected with AdVGag and termed DCGag. DCGag-released exo-
somes (EXOGag) were then puriﬁed from DC culture supernatants
by differential ultracentrifugation [15].
Gag-Texo preparation
The wild-type C57BL/6 or transgenic HLA-A2 mouse spleno-
cytes were cultured in RPMI1640 medium containing IL-2 (20 U/
ml) and ConA (1 lg/ml) for 3 days [37]. ConA-activated CD8+ T
(ConA-T) cells were enriched by passage through nylon wool col-
umns (C&A Scientiﬁc, Manassas, VA), and then puriﬁed by negative
selection using anti-mouse CD8 paramagnetic beads (DYNAL Inc.,
Lake Success, NY) [38]. Gag-Texo vaccine was generated by incuba-
tion of CD8+ ConA-T cells with EXOGag as previously described [17].
Electron microscopic analysis
EXOs were ﬁxed in 4% paraformaldehyde. The pellets were then
loaded onto carbon-coated formvar grids. The EXO sample-loaded
grids were stained with saturated aqueous uranyl, and then exam-
ined with a JEOL 1200EX electron microscope at 60 kV [39].
Western blot analysis
Cell lysates (10 lg/well) were loaded onto 12% acrylamide gels,
subjected to sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis (SDS–PAGE), and subsequently transferred onto nitrocel-
lulose membrane (Millipore, Bedford, MA). The membrane was
blocked with ODYSSEY blocking buffer (Li-COR Bioscience, Lincoln,
NE), immunoblotted with anti-Gag Ab, incubated with anti-goat
IRDyeR800CW Ab, and then scanned using ODYSSEY instrument
according to manufacture’s instruction (Li-COR Bioscience) [39].
Flow cytometric analysis
Cells and EXOs were stained with a panel of Abs and analyzed
by ﬂow cytometry [17]. To assess Gag-Texo stimulated CTL re-
sponses, the blood samples harvested from immunized mice were
stained with FITC-conjugated anti-CD8 Ab (FITC-CD8) and PE-con-
jugated anti-CD44 Ab (PE-CD44), and analyzed by ﬂow cytometry.
In another set of experiments, the spleen cells were harvested from
immunized mice, and depleted of erythrocytes. The splenocytes
were cultured for 4 h with 2 lM Gag peptide (SLYNTVATL), and
then stained with FITC-anti-CD8 Ab. Subsequently, the T cells were
ﬁxed, and cell membranes were permeabilized with Cytoﬁx/Cyto-
perm solution (BD Biosciences). The cells were stained with PE-
conjugated anti-IFN-r Ab, and then analyzed by ﬂow cytometry
[40].
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Fig. 1. Phenotypic analysis of Gag-Texo. (A) Schematic representation of adenoviral (AdV) vector AdVGag. The E1/E3 depleted replication-deﬁcient AdV is under the regulation
of the cytomegalovirus (CMV) early/immediate promoter/enhancer. ITR, inverted terminal repeat. (B) DCGag were stained with a panel of Abs (solid lines) or isotype-matched
irrelevant Abs (dotted lines) and analyzed by ﬂow cytometry. (C) Western blot analysis of lysates of DCGag and DCs using the anti-Gag Ab. (D) Electron micrograph of EXOGag.
Bar, 100 nm. (E) EXOGag were stained with a panel of Abs (solid lines) or isotype-matched irrelevant Abs (dotted lines) and analyzed by ﬂow cytometry. One representative
experiment of two is shown.
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The in vivo cytotoxicity assay was performed as previously de-
scribed [41]. Brieﬂy, splenocytes were harvested from naive
C57BL/6 mouse spleens and incubated with either high (3.0 lM,
CFSEhigh) or low (0.6 lM, CFSElow) concentrations of CFSE, to gener-
ate differentially labeled target cells. The CFSEhigh cells were pulsed
with Gag peptide, whereas the CFSElow cells were pulsed with irrel-
evant HER2 peptide, and served as internal controls. These pep-
tide-pulsed target cells (1  106 cells/mouse) were i.v. co-injected
at 1:1 ratio into immunized mice 6 days after the immunization.
16 h later, the residual Gag-speciﬁc CFSEhigh and irrelevant control
CFSElow target cells remaining in the recipients’ spleens were ana-
lyzed by ﬂow cytometry.Animal studies
To examine the protective antitumor immunity conferred by
Gag-Texo vaccine, the wild-type C57BL/6 or transgenic HLA-A2
mice (n = 8) were injected i.v. with DCGag, Gag-Texo and the control
ConA-stimulated CD8+ T (ConA-T) cells (2  106 cells/mouse),
respectively. The immunized mice were challenged i.v. with
0.5  106 BL6-10Gag/GFP or HLA-A2-expressing BL6-10Gag/A2 cells 6
or 30 days subsequent to the immunization. To examine the ther-
apeutic antitumor immunity conferred by Gag-Texo vaccine, the
transgenic HLA-A2 mice (n = 8) were ﬁrst injected i.v. with
0.5  106 BL6-10Gag/A2 cells. 6 days after tumor cell inocula-
tion, HLA-A2 mice were then injected i.v. with Gag-Texo cells
(2  106 cells/mouse). The mice were sacriﬁced 3 weeks aftertumor cell injection, and the lung metastatic tumor colonies were
counted in a blind fashion. Metastases on freshly isolated lungs
appeared as discrete black pigmented foci that were easily distin-
guishable from normal lung tissues and conﬁrmed by histological
examination. Metastatic foci too numerous to count were assigned
an arbitrary value of >300 [15].
Statistic analyses
Statistical analyses were performed using the Student t test or
the Mann–Whitney U test for comparison of variables from differ-
ent groups. A value of p < 0.05 was considered to be statistically
signiﬁcant [16].
Results
Generation of Gag-Texo vaccine
We previously prepared Gp120-speciﬁc CD8+ T cell-based
vaccine (Gp120-Texo) by using ConA-stimulated CD8+ T cells with
uptake of AdVGp120-infected DC (DCGp120)-released exosomes
(EXOGp120), and showed that Gp120-Texo vaccine stimulated
Gp120-speciﬁc CTL responses and therapeutic immunity [17,18].
To assess whether HIV-1 Gag-speciﬁc T cell-based vaccine can also
stimulate CTL responses and therapeutic immunity, we ﬁrst
constructed a recombinant adenoviral vector AdVGag expressing
HIV-1 Gag (Fig. 1A), and generated bone marrow-derived DCs
which express CD11c, DC maturation markers such as Iab, CD40,
CD80 and CD86 and other costimulatory molecules such as
22 R. Wang et al. / Trials in Vaccinology 3 (2014) 19–254-1BBL and OX40L (Fig. 1B), indicating that they are mature DCs.
We then infected DCs with AdVGag to form DCGag. We showed that
DCGag expressed HIV-1 Gag (55 KDa) assessed by Western Blotting
analysis (Fig. 1C). We also puriﬁed DCGag-released EXO (EXOGag)
from DCGag culture supernatants by ultracentrifugation. We dem-
onstrated that EXOGag showed a typical exosomal characteristic
of ‘‘saucer’’ or round shape with a diameter between 50 and
90 nm (Fig. 1D), and similarly expressed the above DC’s molecules,
but at much less content than DCs (Fig. 1E).Gag-Texo vaccine stimulates Gag-speciﬁc effector CTL responses in
C57BL/6 mice
We then immunized C57BL/6 mice with Gag-Texo and DCGag,
and then assessed CTL responses by ﬂow cytometry using FITC-
anti-CD8 and PE-anti-CD44 antibodies for double staining 6 days
after immunization [17,18]. We demonstrated that both Gag-Texo
and DCGag vaccines were capable of more efﬁciently stimulating
proliferation of CTLs expressing T cell activation marker CD44
than ConA-T cells (p < 0.05) (Fig. 2A). In addition, we also quanti-
ﬁed Gag-speciﬁc CTL responses in Gag-Texo- and DCGag-immu-
nized mice by ﬂow cytometry using FITC-anti-CD8 and PE-anti-
IFN-c antibodies for double staining after in vitro Gag peptide
stimulation of splenocytes puriﬁed from the immunized mice.
We found that 3.76% and 5.61% of CD8+ T-cells from Gag-Texo-
and DCGag-immunized mice produced IFN-c, which is signiﬁcantly
more than CD8+ T-cells (1.31%) from ConA-T-immunized mice1.89 1.93
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Fig. 2. Gag-Texo stimulates Gag-speciﬁc functional effector CTL responses. (A, B) C57BL
without uptaking EXOGag. 6 days after the immunization, tail blood samples of the immu
by ﬂow cytometry. In another set of experiments, the splenocytes of immunized mice wer
After cell membrane permeabilization, the cells were stained with PE-anti-IFN-r Ab, and
of CD8+ CD44+ T cells in the total cells analyzed or the percentage of CD8+ T cells producin
the immunization, the immunized mice were i.v. injected with a mixture of CFSEhigh an
irrelevant Mut1 peptide, respectively. After 16 h, the spleens of immunized mice were re
remaining in the recipients’ spleens were analyzed by ﬂow cytometry. The value in each
spleen. The value in parenthesis represents the standard deviation (SD). ⁄p < 0.05 versu
shown.(p < 0.05) (Fig. 2B), indicating that both Gag-Texo and DCGag stim-
ulate efﬁcient Gag-speciﬁc CTL responses. Next, we assessed the
ability of Gag-Texo to induce the differentiation of stimulated
CD8+ T-cells into effector CTLs. We adoptively transferred
Gag76–84 peptide-pulsed splenocytes that had been strongly la-
beled with CSFE (CFSEhigh), as well as the control HER2 peptide-
pulsed splenocytes that had been weakly labeled with CFSE
(CFSElow) at 1:1 ratio, into recipient mice that had been vacci-
nated with either Gag-Texo or DCGag cells 6 days after immuniza-
tion. 16 hours after the cell transfer, mouse splenocytes were
analyzed by ﬂow cytometry. Thus, the loss of Gag-speciﬁc
CFSEhigh target cells represents the Gag-speciﬁc killing activity
of CTLs in immunized mice. As expected, there was substantial
loss (72% and 80%) of the CFSEhigh cells in the Gag-Texo- and
DCGag-immunized mice, respectively, whereas little cytotoxicity
(3%) was induced in control ConA-T-immunized mice (Fig. 2C),
indicating that Gag-Texo- and DCGag-stimulated CTLs are effector
CTLs with Gag-speciﬁc cellular cytotoxicity.Gag-Texo vaccine stimulates protective antitumor immunity in C57BL/
6 mice
Next, we transfected BL6-10 cells with pcDNA-Gag/GFP
expression vector to form BL6-10Gag melanoma cells expressing a
ﬂuorescent fusion protein Gag/GFP (Fig. 3A, panel a), but not
HLA-A2 (Fig. 3A, panel c) by ﬂow cytometric analysis. Expression
of Gag portion of Gag/GFP (82 KDa) was conﬁrmed using4.92
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Fig. 3. Gag-Texo stimulates preventive anti-tumor immunity. (A) Gag/GFP expression in BL6-10Gag (solid lines) or BL6-10 cells (dotted lines) was analyzed by ﬂow cytometry
(panel a). BL6-10Gag and BL6-10 cells were stained with the anti-HLA-A2 Ab and analyzed by ﬂow cytometry (panels b and c). (B) Western blot analysis of lysates of BL6-10Gag
and BL6-10 cells using the anti-Gag Ab. (C) C57BL/6 mice were immunized with PBS, ConA T, or Gag-Texo or DCGag. 6 days after the immunization, the immunized mice were
i.v. injected with BL6-10Gag cells, then sacriﬁced 3 weeks subsequent to tumor challenge. The lung samples were collected and metastatic tumor colonies were counted. One
representative experiment of two is shown.
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assessed the protective immunity derived from Gag-Texo vaccine
against B16 melanoma BL6-10Gag by i.v. injection of BL6-10Gag cells
into immunized C57BL/6 mice 6 days after immunization. 3 weeks
after tumor cell injection, mice were sacriﬁced, and mouse lungs
were checked for tumor metastasis colonies. As shown in Fig. 3C,
all mice injected with ConA-T cells without uptake of EXOGag had
large numbers (>300) of lung metastatic BL6-10Gag tumor colonies.
Gag-Texo or DCGag vaccine, however, induced a complete immune
protection against BL6-10Gag tumor cell challenge in all 8/8 (100%)
mice, indicating that Gag-Texo induces efﬁcient protective immu-
nity in wild-type C57BL/6 mice.Gag-Texo vaccine induces protective and long-term antitumor
immunity in transgenic HLA-A2 mice
Next, we generated BL6-10Gag/A2 melanoma cells by transfection
of BL6-10Gag/GFP cells with pcDNA-HLA-A expression vector, and
showed that transfected BL6-10Gag/A2 melanoma cells expressed
both HLA-A2 and Gag (Fig. 4A, panels a/d and b/d). We then as-
sessed the protective (6 days after immunization) and long-term
immunity (30 days after immunization) derived from Gag-Texo
vaccine against B16 melanoma BL6-10Gag/A2. As shown in Fig. 4B,
all mice injected with ConA-T cells without uptake of EXOGag had
a large number (>300) of lung metastatic BL6-10Gag/A2 tumor colo-
nies. Gag-Texo vaccine, however, induced immune protection
against BL6-10Gag/A2 tumor-cell challenge in 8/8 (100%) and 2/8
(25%) HLA-A2 mice with 6 and 30 days post immunization, respec-
tively. The average number of lung tumor colonies in mice with
30 days post immunization is only 23, which is signiﬁcantly less
than that (>300) in control ConA-T-immunized mice (p < 0.05).
Our data indicate that Gag-Texo induces both protective and
long-term immunity in HLA-A2 mice.Gag-Texo vaccine induces therapeutic immunity against Gag/HLA-A2-
expressing tumor in transgenic HLA-A2 mice
To assess the potential therapeutic effect of Gag-Texo, we ﬁrst
challenged HLA-A2mice with BL6-10Gag/A2 tumor cells. 6 days after
tumor cell challenge, mice were then immunized with Gag-Texo.
We found that, though all Gag-Texo-immunized mice (8/8) post
6-day tumor-cell challenge still carried lung tumor metastasis,
the average number (50) and size (0.23 mm in diameter) of lung
tumor colonies in Gag-Texo-immunized mice are signiﬁcantly less
than the average number (>300) and size (1.02 mm in diameter) in
control ConA-T-immunized mice (p < 0.05) (Fig. 4C), indicating
that Gag-Texo vaccine also induces some degree of therapeutic
immunity against 6-day-established lung tumor metastasis in
transgenic HLA-A2 mice.Discussion
We previously generated Gp120-Texo vaccine using ConA-T-
stimulated mouse polyclonal CD8+ T cells with uptake of HIV-1
Gp120-speciﬁc DC-released EXO (EXOGp120), and demonstrated
that CD8+ Gp120-Texo vaccine is capable of stimulating CD4+ T
cell-independent Gp120-speciﬁc CTL responses leading to protec-
tive and long-term immunity against Gp120/HLA-A2-expressing
B16 melanoma (BL6-10Gp120/A2) in 8/8 transgenic HLA-A2 mice
[17,18]. In addition, CD8+ Gp120-Texo vaccine also induced com-
plete therapeutic immunity against 6-day-established lung BL6-
10Gp120/A2 melanoma metastasis in 2/8 HLA-A2 mice [17,18]. Since
Gag has become one of the most attractive target candidates for
HIV-1 vaccine development, we generated Gag-Texo vaccine in this
study. We demonstrate that both Gag-Texo and DCGag vaccines are
capable of comparably stimulating Gag-speciﬁc effector CD8+ CTL
responses. We also show that Gag-Texo-stimulated CTL response
results in protective immunity against Gag-expressing BL6-10Gag
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 Mean of metastatic
 tumor colonies            >300               >300            23 (13-32)* 
PBS              ConA T      Gag-Texo
Fig. 4. Gag-Texo induces preventive and therapeutic anti-tumor immunity in HLA-
A2 mice. (A) BL6-10Gag/A2 cells were stained with FITC-anti-HLA-A2 Ab (solid lines)
or isotype-matched irrelevant Ab (dotted lines) and analyzed by ﬂow cytometry
(panel a). In addition, Gag/GFP expression in BL6-10Gag/A2 (solid lines) or BL6-10
cells (dotted lines) was analyzed with ﬂow cytometry (panel b). BL6-10Gag/A2 cells
were also stained with PE-anti-HLA-A2 Ab, and the cells were then analyzed for PE-
HLA-A2 and GFP-Gag expression by ﬂow cytometry (panels c and d). (B) To assess
protective and long-term immunity, HLA-A2 mice were i.v. injected with BL6-10Gag/
A2 6 or 30 days after PBS, ConA-T, or Gag-Texo immunization. (C) To assess
therapeutic immunity, HLA-A2 mice were i.v. injected with BL6-10Gag/A2. 6 days
after tumor challenge, mice were then vaccinated with after ConA-T, or Gag-Texo.
The mice were sacriﬁced 3 weeks after tumor cell challenge. The average number
and diameter of lung metastatic tumor colonies were counted and measured using
a caliper, respectively. ⁄p < 0.05 versus cohorts of ConA-T cells (Mann–Whitney U
test) and ⁄⁄p < 0.05 versus cohorts of ConA-T cells (Student t test). One represen-
tative experiment of two is shown.
24 R. Wang et al. / Trials in Vaccinology 3 (2014) 19–25melanoma in 8/8 wild-type C57BL/6 mice. In addition, we show
that Gag-Texo vaccine also induces Gag-speciﬁc CTL responses
leading to protective and long-term immunity against Gag/HLA-
A2-expressing BL6-10Gag/A2 melanoma in 8/8 and 2/8 transgenicHLA-A2 mice, respectively. However, the average number of lung
tumor colonies in the remaining 6 mice is only 23, which is signif-
icantly less than that (>300) in control ConA-T-immunized mice. In
addition, Gag-Texo vaccine also induces some degree of therapeu-
tic immunity against 6-day-established lung tumor metastasis in
transgenic HLA-A2 mice. Although all Gag-Texo-immunized mice
(8/8) post 6-day tumor-cell challenge still carried lung tumor
metastasis, the average number (50) and size (0.23 mm in diame-
ter) of lung tumor colonies in Gag-Texo-immunized mice is signif-
icantly less than the average number (>300) and size (1.02 mm in
diameter) in control ConA-T-immunized mice. Compared to
Gp120-Texo vaccine inducing therapeutic immunity against 6-
day-established lung BL6-10Gp120/A2 melanoma metastasis in 2/8
HLA-A2 mice, Gag-Texo vaccine induces a relatively less efﬁcient
therapeutic immunity in HLA-A2 mice bearing 6-day-established
lung BL6–10Gag/A2 melanoma. It was demonstrated that B16 mela-
noma expressing a low density of tumor antigen-speciﬁc pMHC-I
complexes became less sensitive to CTL killing [42]. The less effec-
tiveness of therapeutic immunity in Gag-Texo-immunized mice
may be due to the lower density of Gag-speciﬁc peptide/MHC-I
(pMHC-I) complexes presented on target BL6-10Gag/A2 cells
expressing both Gag and irrelevant GFP, compared to the higher
density of Gp120-speciﬁc pMHC-I complexes presented on
BL6–10Gp120/A2 cells carrying only Gp120. Costimulatory molecule
4-1BBL has been shown to play important role in CTL priming
and memory development, and in rescuing functionally impaired
HIV-1-speciﬁc CTLs [43,44]. To improve effectiveness of Gag-Texo
vaccine, we are currently engineering Gag-Texo vaccine to express
transgene-encoded 4-1BBL, and assessing its enhanced stimulatory
effect on Gag-speciﬁc CTL responses and antitumor immunity in
transgenic HLA-A2 mice.
HIV-1 patients often have CD4+ T cell deﬁciency derived from
the binding of HIV-1 gp120 to T cell CD4 molecules leading to T cell
death by viral cytopathic effect [45]. Since CD4+ T cells are required
for CD8+ CTL response and memory development [46], the quanti-
tative and qualitative nature of HIV-1-speciﬁc CD8+ T cells has
been greatly affected in HIV-1 patients [47]. HIV-1-speciﬁc DC vac-
cines have been also applied to clinical trials [9–12]. However,
these DC vaccines which are capable of HIV-1-speciﬁc CTL re-
sponses in the presence of CD4+ T cells have been found to only in-
duce some degree of immune responses in these studies [13].
Therefore, the quality of CTL responses may be the key to HIV-1
control [48]. Since HIV-1-speciﬁc CD8+ CTLs have been found to
recognize some Gag conserved and cross-strain epitopes
[21,29,30], Gag, but not Gp120 becomes one of the most attractive
target candidates for HIV-1 vaccine development. Our HIV-1 Gag-
speciﬁc DC-released exosome-targeted CD8+ T cell-based Gag-Texo
vaccine may thus bypass the high mutation problem faced by pre-
ventive vaccines for induction of Abs [49], and become more efﬁ-
cient HIV-1 vaccine than our previously reported Gp120-Texo
one [17,18]. Our previous data showed that HIV-1 Gp120-Texo,
but not DCGp120 vaccine stimulated Gp120-speciﬁc CD8+ T cells in
the absence of CD4+ T cells [17,18], indicating that our Gag-Texo
vaccine may similarly stimulate CD4+ T cell-independent Gag-spe-
ciﬁc CTL responses. Although both Gag-Texo and DCGag vaccines
stimulate comparable CTL responses, Gag-Texo vaccine may be-
come more useful for treatment of HIV-1 patients with CD4+ T cell
deﬁciency than DCGag. The assessment of Gag-speciﬁc CTL re-
sponses in patient’s blood samples, which are stimulated in vitro
by Gag-Texo cells derived from patient’s autologous T cells with
uptake of AdVGag-transfected autologous DC-released exosomes,
is currently underway in our laboratory.
Taken together, our novel CD8+ Gag-Texo vaccine capable of
stimulating Gag-speciﬁc effector CTL responses and therapeutic
immunity in transgenic HLA-A2 mice may be useful as a new
immunotherapeutic vaccine for viral control in HIV-1 patients.
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